BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade®, a ...

Boruzu is the first ready-to-use bortezomib injection for multiple myeloma and mantle cell lymphoma, and lowers the compounding preparation process needed for administration. A proteasome ...

A recent phase I trial has demonstrated that bortezomib, in combination with pegylated liposomal doxorubicin, can be safely administered to patients with advanced hematologic malignancies.

A multicenter team from the US reports on the frequency of and risk factors for thrombocytopenia in patients receiving bortezomib for relapsed or refractory multiple myeloma. The data, from the ...

Included in the list are medicines for cancer: Bortezomib 3.5 mg (powder for injection); Docetaxel (as trihydrate) 20 mg/mL (80 mg/4mL) (concentrate for solution for IV infusion); Lenvatinib (as ...

BORUZU™ (bortezomib injection), a proteasome inhibitor, is used for the treatment of multiple myeloma and mantle cell lymphoma. This product references the branded product Velcade®, a lyophilized ...